Table 2.
Developments in delivery nanosystems of miRNAs for therapy MetS.
| NA | Nanocarrier Classification | Composition and Feature | Disease | Target Strategies | References |
|---|---|---|---|---|---|
| siPPARA | Exosomes | Exosomes isolated from plasma | Obesity | - | [93] |
| miR-21 mimic and inhibitor | Exosomes | Peripheral blood-derived exosomes | MI | - | [91] |
| cholesterol-modified miR-210 | Exosomes | Conjugated c(RGDyK) peptide on mesenchymal stromal cell (MSC)-derived exosomes | Cerebral ischemia | Peptide target Ischemia part | [90] |
| miR-155 mimic | Exosomes | ATM-derived exosomes | IR | - | [92] |
| miR-192-5p inhibitor | Exosomes | Exosomes isolated from serum | NAFLD | - | [117] |
| miR-103/107 antagomirs | Liposomes | Liposomes were composed of DLin-KC2-DMA, distearoyl phosphatidylcholine, cholesterol and mPEG2000-DMG, used at the molar ratio 50:10:38.5:1.5 | T2DM | - | [118] |
| miR-106b, miR-148b, and miR-204 mimics | Liposomes | Cationic lipid: DOTAP | MI | - | [119] |
| anti-miR-712 | Liposomes | DOTAP: DSPE-PEG2k:HSPC:chol (9.3:3.1:52.6:35, molar ratio) | AS | - | [120] |
| anti-miR-1 antisense oligonucleotides | Liposomes | anti-cardiac troponin I (cTnI) antibody modified liposomes (EPC, CHO and DSPE-PEG2000, with molar ratio of 49/50/1) | Ischemic myocardium | - | [100] |
| miR-182 inhibitor | Liposomes | CHO/PGEA | Cardiac hypertrophy | - | [102] |
| siFVII | Liposomes | DSPC, PEG-lipid, CHO | Liver disease | - | [101] |
| siFVII | Liposomes | N-acetylgalactosamine (GalNAc)–PEG–lipid | Liver disease | Receptor target liver | [121] |
| miR-33 mimic | Polymers | Chitosan via the ionic gelation method using TPP as a cross-linker | AS | Inflammation | [114] |
| anti-miR33 | Polymers | pH-responsive polymers synthesized by acetylation of cyclo-dextrins (CDs) and DSPE-PEG | AS | pH-response | [122] |
| miR-199a-3p mimic | Polymers | a core−shell structure: PFBT core, PEG shell, and TAT conjugate on the surface of NPs | MI | - | [116] |
| miR-21 mimic | Polymers | spontaneously assembled due to the complexation of hyaluronan-sulfate with the NA mediated by calcium ion bridges | MI | - | [115] |
| sipcsk9 | Polymers | PLGA: DOTAP (ratio of 20:3), platelets membrane coating | Hypercholesterolemia | - | [109] |
| siapoB | Polymers | The micellar NPs assembled in aqueous solution from mixed N-acetylgalactosamine (GalNAc) functionalized PCL-b-PPEEA | Liver disease | Receptor target liver | [123] |
| miR-133a | Inorganic nanomaterials | negatively charged calcium phosphate nanoparticles | CVD | - | [124] |